The FDA has approved a five-day, once-daily IV and oral 750-mg regimen of levofloxacin (Levaquin drug, Ortho-McNeil, PriCara) for patients with complicated urinary tract infections (UTIs) and acute pyelonephritis (kidney infection).
This approval was based on results of a double-blind, randomized clinical trial. Since its U.S. introduction in 1996, generic levofloxacin has been used to treat adults with bacterial infections caused by sus ceptible pathogens, including acute bacterial sinusitis; acute bacterial exacerbation of chronic bronchitis; nosocomial pneumonia; community-acquired pneumonia, complicated skin and skin structure infections; mild-to-moderate, uncomplicated skin and skin structure infections; chronic bacterial prostatitis; mild to moderate complicated and uncomplicated UTIs (10-day regimen); complicated UTIs (five-day regimen); acute pyelonephritis; and post-exposure inhalational anthrax.
Levofloxacin is available in 250-mg, 500-mg and 750-mg doses in both IV and oral formulations.
Sources: FDA, September 17, 2007